Psoriatic arthritis [version 1; peer review: 2 approved]

Psoriasis is a multisystemic, inflammatory skin condition that can affect many areas of the body, but most commonly the extensor surfaces of the elbows and knees, and sometimes the intergluteal and umbilical area. It has a prevalence of 2–4% in western adults, and 20­–30% of psoriasis patients will...

Full description

Bibliographic Details
Main Authors: Vanessa Ocampo D, Dafna Gladman
Format: Article
Language:English
Published: F1000 Research Ltd 2019-09-01
Series:F1000Research
Online Access:https://f1000research.com/articles/8-1665/v1
id doaj-e75c907e095f48a2932664a049b4c004
record_format Article
spelling doaj-e75c907e095f48a2932664a049b4c0042020-11-25T03:44:00ZengF1000 Research LtdF1000Research2046-14022019-09-01810.12688/f1000research.19144.120979Psoriatic arthritis [version 1; peer review: 2 approved]Vanessa Ocampo D0Dafna Gladman1University of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, CanadaUniversity of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, CanadaPsoriasis is a multisystemic, inflammatory skin condition that can affect many areas of the body, but most commonly the extensor surfaces of the elbows and knees, and sometimes the intergluteal and umbilical area. It has a prevalence of 2–4% in western adults, and 20­–30% of psoriasis patients will develop psoriatic arthritis (PsA). PsA is an inflammatory musculoskeletal disease associated with cutaneous psoriasis. It affects men and women almost equally with a peak age at onset of 40 and 50 years. It is a diverse disease that affects multiple organ systems includes peripheral and axial joints, entheses, skin, and nails. PsA is associated with comorbidities such as osteoporosis, uveitis, subclinical bowel inflammation, and cardiovascular disease. Given this heterogeneity, its diagnosis has been difficult. Here we present an updated review of its classification criteria CASPAR (classification criteria for PsA), use of screening tools to aid in early diagnosis, recent findings on pathogenesis, and new therapeutic approaches including new biologic medications.https://f1000research.com/articles/8-1665/v1
collection DOAJ
language English
format Article
sources DOAJ
author Vanessa Ocampo D
Dafna Gladman
spellingShingle Vanessa Ocampo D
Dafna Gladman
Psoriatic arthritis [version 1; peer review: 2 approved]
F1000Research
author_facet Vanessa Ocampo D
Dafna Gladman
author_sort Vanessa Ocampo D
title Psoriatic arthritis [version 1; peer review: 2 approved]
title_short Psoriatic arthritis [version 1; peer review: 2 approved]
title_full Psoriatic arthritis [version 1; peer review: 2 approved]
title_fullStr Psoriatic arthritis [version 1; peer review: 2 approved]
title_full_unstemmed Psoriatic arthritis [version 1; peer review: 2 approved]
title_sort psoriatic arthritis [version 1; peer review: 2 approved]
publisher F1000 Research Ltd
series F1000Research
issn 2046-1402
publishDate 2019-09-01
description Psoriasis is a multisystemic, inflammatory skin condition that can affect many areas of the body, but most commonly the extensor surfaces of the elbows and knees, and sometimes the intergluteal and umbilical area. It has a prevalence of 2–4% in western adults, and 20­–30% of psoriasis patients will develop psoriatic arthritis (PsA). PsA is an inflammatory musculoskeletal disease associated with cutaneous psoriasis. It affects men and women almost equally with a peak age at onset of 40 and 50 years. It is a diverse disease that affects multiple organ systems includes peripheral and axial joints, entheses, skin, and nails. PsA is associated with comorbidities such as osteoporosis, uveitis, subclinical bowel inflammation, and cardiovascular disease. Given this heterogeneity, its diagnosis has been difficult. Here we present an updated review of its classification criteria CASPAR (classification criteria for PsA), use of screening tools to aid in early diagnosis, recent findings on pathogenesis, and new therapeutic approaches including new biologic medications.
url https://f1000research.com/articles/8-1665/v1
work_keys_str_mv AT vanessaocampod psoriaticarthritisversion1peerreview2approved
AT dafnagladman psoriaticarthritisversion1peerreview2approved
_version_ 1724516827037433856